<DOC>
	<DOCNO>NCT00402233</DOCNO>
	<brief_summary>Primary objective : ass efficacy pramipexole give two time daily compare placebo . Secondary objective : ass effect pramipexole mood , cognition , fatigue , impulse control , daytime sleepiness nighttime sleep compare placebo ; compare tolerability among treatment group 12 week</brief_summary>
	<brief_title>A Randomized , Double-blind , Active ( Pramipexole 0.5 mg Tid ) Placebo Controlled , Study Pramipexole Given 0.5 mg 0.75 mg Bid Over 12-week Treatment Early Parkinson 's Disease ( PD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Potential subject must meet follow inclusion criterion eligible enrollment study : 1 . Must willing able give inform consent . 2 . Must 30 year age Baseline . 3 . Must idiopathic Parkinson 's disease le 7 year duration since diagnosis , characterize 2 follow 3 cardinal sign ( sign need asymmetric ) : rest tremor , bradykinesia rigidity . 4 . Must Modified Hoehn Yahr stage &lt; 3 . 5 . Should able safely tolerate placebo 12 week Baseline . 6 . Must negative urine pregnancy test Screening Visit use adequate contraceptive method throughout study woman childbearing potential . Women surgically sterile ( hysterectomy tubal ligation ) whose last menstruation 12 month prior Screening Visit consider nonchildbearing potential . Acceptable form contraception include oral , implanted , injected contraceptive intrauterine device place least 3 month estrogen patch adequate barrier method conjunction spermicide . Abstinence consider acceptable contraceptive regimen . 7 . Must willing able comply trial procedure . They must sufficiently proficient English understand complete study instrument . Individuals follow characteristic eligible entry study : 1 . Signs symptoms suggest parkinsonian syndrome . 2 . Use medication may cause secondary parkinsonism , include limited : neuroleptic , metaclopramide , alphamethyldopa , flunarizine , methylphenidate , cinnarizine , reserpine , amphetamine last 6 month prior Baseline Visit . 3 . Use dopaminergic medication within last 3 month longer 6 month prior Baseline Visit . 4 . Presence dementia Diagnostic Statistical Manual Mental Disorders IV criterion ( R061340 ) Mini Mental State Examination ( R962656 ) ( Appendix 10.1 ) score le 26 Screening Visit . 5 . Presence major depression , determine medical history . 6 . Active epilepsy ( i.e. , occurrence seizure ) within past year prior Baseline Visit . 7 . Electro Convulsive Therapy previous 90 day prior Baseline Visit . 8 . Myocardial infarction within previous 6 month prior Baseline Visit . 9 . Third degree atrioventricular block sick sinus syndrome . 10 . Congestive heart failure Class III IV New York Heart Association classification . 11 . Symptomatic orthostatic hypotension Screening Visit . 12 . Stereotaxic brain surgery . 13 . Clinically significant liver disease . 14 . Clinically significant renal disease . 15 . Any clinically significant medical psychiatric condition ( e.g. , angina , active neoplasm ) judgment investigator would interfere subject ability participate study would jeopardize safe conduct study . 16 . Breastfeeding . 17 . Known hypersensitivity intolerability pramipexole . 18 . Participating drug study receive experimental medication within 30 day Baseline Visit . 19 . History drug alcohol dependency within 6 month baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>31 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>